Jodi A Braley

Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease.

Anna L. Brown, Paul P. S. Wang, D. Thomson, 2018, Blood.

TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets.

C. Tam, A. Schwarer, D. White, 2015, Blood.

Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline.

Nicola D. Roberts, J. Seymour, T. Hughes, 2014, Blood.

with for

Christopher, C. Tam, A. Schwarer, 2014 .

Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission

D. White, T. Hughes, C. Kok, 2019, Leukemia.

Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia.

Dong-Wook Kim, T. Hughes, S. Branford, 2020, Blood.

Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment

D. J. Moulton, E. Nievergall, C. Mullighan, 2014, Leukemia.